// AI news · 2026-11-13 · HIT Consultant
Orakl Oncology Raises $34M for Cancer Trial Outcome Prediction
Orakl Oncology raised $34M in Series A funding co-led by Norrsken VC and Singular to scale its AI platform for predicting cancer clinical trial outcomes.
Published 2026-11-13 00:15 (Beijing time)Source HIT ConsultantAuto-summarised, fact-checked against source
01Summary
The platform uses patient-derived tumor organoids combined with machine learning to achieve 90% accuracy in forecasting trial results. It has established commercial partnerships with 18 of the world’s top 20 pharmaceutical companies and is expanding into new cancer indications and upstream target discovery.
Summarised from the original article by an open-source model, then checked automatically: every number and English name must appear in the source. The original article is authoritative.
02Key points
- Orakl Oncology raised $34M in Series A co-led by Norrsken VC and Singular.
- Platform achieves 90% accuracy in predicting clinical trial outcomes using organoid-based AI models.
- Active partnerships with 18 of the world’s top 20 pharma companies.
- Expanding into new cancer types and upstream therapeutic target discovery.
03Source
Orakl Oncology Raises $34M to Predict Cancer Clinical Trial Outcomes with 90% Accuracy
HIT Consultant · published 2026-11-13 00:15 Beijing time
Also reported by 1 other outlet
05Related news
From AIMap AI news: collected from 1,100+ official and media sources. Summaries only restate the original article; follow the link for the full story. All stories of 2026-11-13 · Archive by date · All AI news · Today